ATE459883T1 - Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose - Google Patents

Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose

Info

Publication number
ATE459883T1
ATE459883T1 AT05715950T AT05715950T ATE459883T1 AT E459883 T1 ATE459883 T1 AT E459883T1 AT 05715950 T AT05715950 T AT 05715950T AT 05715950 T AT05715950 T AT 05715950T AT E459883 T1 ATE459883 T1 AT E459883T1
Authority
AT
Austria
Prior art keywords
diagnosis
cancer prognosis
proliferation markers
clinical practice
new proliferation
Prior art date
Application number
AT05715950T
Other languages
English (en)
Inventor
Genevieve Almouzni
Sophie E Polo
Stamatios E Theocharis
Philippe Vielh
Original Assignee
Inst Curie
Centre Nat Rech Scient
Univ Paris Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Curie, Centre Nat Rech Scient, Univ Paris Curie filed Critical Inst Curie
Application granted granted Critical
Publication of ATE459883T1 publication Critical patent/ATE459883T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT05715950T 2004-02-27 2005-02-28 Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose ATE459883T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54811104P 2004-02-27 2004-02-27
PCT/EP2005/002578 WO2005085860A2 (en) 2004-02-27 2005-02-28 New proliferation markers in clinical practice and their use for cancer prognosis or diagnosis

Publications (1)

Publication Number Publication Date
ATE459883T1 true ATE459883T1 (de) 2010-03-15

Family

ID=34919336

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05715950T ATE459883T1 (de) 2004-02-27 2005-02-28 Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose

Country Status (7)

Country Link
US (2) US7781174B2 (de)
EP (1) EP1721165B1 (de)
JP (1) JP4848355B2 (de)
AT (1) ATE459883T1 (de)
CA (1) CA2555656C (de)
DE (1) DE602005019694D1 (de)
WO (1) WO2005085860A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11254916B2 (en) 2006-03-02 2022-02-22 Viacyte, Inc. Methods of making and using PDX1-positive pancreatic endoderm cells
JP6110048B2 (ja) 2006-03-02 2017-04-05 ヴィアサイト，インコーポレイテッド 内分泌前駆細胞、膵臓ホルモン発現細胞及びそれらの製造方法
WO2008035692A1 (fr) * 2006-09-19 2008-03-27 Jcr Pharmaceuticals Co., Ltd. Marqueur d'identification de cellule cancéreuse et inhibiteur de prolifération de cellule cancéreuse
JP5167350B2 (ja) 2007-05-30 2013-03-21 エフ．ホフマン−ラ ロシュ アーゲー 非ヌクレオシド系逆転写酵素阻害剤
EP2271775A4 (de) 2008-04-08 2011-09-07 Nuclea Biomarkers Llc Biomarkergruppe zur vorhersage des wiederauftretens von kolorektalkarzinom
EP2243843A1 (de) * 2009-04-24 2010-10-27 Institut Curie HP1-Alpha als prognostischer Marker bei Krebserkrankungen des Menschen
WO2011151321A1 (en) 2010-05-31 2011-12-08 Institut Curie Asf1b as a prognosis marker and therapeutic target in human cancer
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
EP3304084B1 (de) 2015-06-08 2022-03-23 Arquer Diagnostics Limited Verfahren und kits
JP6854246B2 (ja) 2015-06-08 2021-04-07 アーケア ダイアグノスティクス リミテッド 尿サンプルの分析方法
JP6841609B2 (ja) 2015-07-10 2021-03-10 ３スキャン インコーポレイテッド 組織学的染色の空間的多重化
CA3058406A1 (en) 2017-03-30 2018-10-04 The Board Of Trustees Of The University Of Illinois Method and kit for diagnosing early stage pancreatic cancer
CN111819443A (zh) 2018-02-28 2020-10-23 日东纺绩株式会社 从固定化细胞或ffpe组织切片脱离增强抗原性的细胞核的方法以及用于该方法的抗原活化剂及试剂盒
CN111766385B (zh) * 2020-07-06 2023-09-26 河南赛诺特生物技术有限公司 术中快速鉴别肺癌和硬化性肺细胞瘤的免疫组化试剂盒
CN113984483B (zh) * 2021-09-28 2023-10-20 福建医科大学 一种冰冻切片盖玻片贴片染色方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071715A (en) * 1993-08-12 2000-06-06 Board Of Regents, The University Of Texas System Nucleic acids encoding novel proteins which bind to retinoblastoma protein
CN1721554B (zh) * 2000-11-24 2010-05-26 卫材R&D管理有限公司 试验肿瘤细胞对于抗癌药剂敏感性的方法
AU2002330039A1 (en) * 2001-09-17 2003-04-01 Eos Biotechnology, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
US20040005644A1 (en) * 2002-02-28 2004-01-08 Su Yan A. Method and composition for detection and treatment of breast cancer

Also Published As

Publication number Publication date
US7781174B2 (en) 2010-08-24
JP4848355B2 (ja) 2011-12-28
CA2555656A1 (en) 2005-09-15
EP1721165A2 (de) 2006-11-15
WO2005085860A3 (en) 2005-11-10
EP1721165B1 (de) 2010-03-03
US20070077577A1 (en) 2007-04-05
CA2555656C (en) 2017-03-28
JP2007524103A (ja) 2007-08-23
DE602005019694D1 (de) 2010-04-15
WO2005085860A2 (en) 2005-09-15
US20110003706A1 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
ATE459883T1 (de) Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose
WO2008091814A3 (en) Assessment of asthma and allergen-dependent gene expression
DK1666052T3 (da) Anti-APRIL monoklonalt antistof og dets anvendelse til behandling af en immum-relateret sygdom eller cancer
WO2006047484A3 (en) Molecular analysis of cellular fluid and liquid cytology specimens for clinical diagnosis, characterization, and integration with microscopic pathology evaluation
AU2007255110A8 (en) Circulating tumor cell assay
ATE519110T1 (de) Diagnostischer nanosensor und dessen verwendung in der medizin
WO2007092433A3 (en) Osteoporosis associated markers and methods of use thereof
WO2008109414A3 (en) Use of endogenous fluorescence to identify invading metastatic breast tumor cells
WO2010118166A3 (en) Methods of predicting cancer risk using gene expression in premalignant tissue
MY193895A (en) Combination test for colorectal cancer
MX2020002122A (es) Sustancias de control de calidad para uso con analizadores de sedimentos en orina basados en microscopia, y metodos de uso.
Singh et al. Immunohistochemical expression levels of p53 and eIF4E markers in histologically negative surgical margins, and their association with the clinical outcome of patients with head and neck squamous cell carcinoma
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
ATE430936T1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
DE60315715D1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
ATE479898T1 (de) Reagenzien und verfahren zur verwendung bei der diagnose, klassifizierung und behandlung von krebs
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs
WO2013072584A3 (fr) Méthode de caractérisation de cellules tumorales circulantes et application au diagnostic
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
ATE512146T1 (de) Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen
ATE414701T1 (de) Fluoreszenzsonden zur verwendung bei einem bindungsassay auf proteinkinaseinhibitoren
EP1937831A4 (de) Verwendung von n-myristoyltransferase auf nichttumorgewebe zur krebsdiagnose
WO2007020522A3 (en) Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type
DE602004001994D1 (de) Verwendung des proteins masp als marker für kolorektale karzinome

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties